Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | MYC | P01106 | 2/20 | 0.44 |
| ▸ | MAX | P61244 | 2/20 | 0.44 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | PELP1 | Q8IZL8 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30623210 | 0.90 | VCAM1 (0.50) | VCAM1ALDH1A1PKMLMNAHPGD | |
| SCHEMBL26122443 | 0.90 | VCAM1 (0.50) | VCAM1ALDH1A1PKMLMNAHPGD | |
| SCHEMBL25877473 | 0.86 | LMNA (0.46) | ALDH1A1PKMLMNAHTTKMT2A | |
| SCHEMBL27111002 | 0.82 | VCAM1 (0.45) | VCAM1ALDH1A1PKMLMNAHPGD | |
| SCHEMBL24140593 | 0.80 | HDAC1 (0.50) | ALDH1A1HPGDNPSR1 | |
| SCHEMBL30028874 | 0.79 | VCAM1 (0.43) | VCAM1ALDH1A1PKMLMNAHPGD | |
| SCHEMBL223175 | 0.78 | VCAM1 (0.57) | VCAM1ALDH1A1PKMLMNAHPGD | |
| SCHEMBL29557079 | 0.78 | VCAM1 (0.57) | VCAM1ALDH1A1PKMLMNAHPGD | |
| SCHEMBL30028806 | 0.78 | VCAM1 (0.44) | VCAM1ALDH1A1PKMLMNAHPGD | |
| SCHEMBL24958856 | 0.78 | VCAM1 (0.44) | VCAM1ALDH1A1PKMLMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| WO-2021263079-A1 | TREX1 INHIBITORS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | FEN1, ERCC4, DCLRE1B | VCAM1 3452/4885ALDH1A1 1451/4885PKM 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.